Compare Flagstar Bank NA (FLG) vs Neurocrine Biosciences Inc (NBIX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Flagstar Bank NA vs Neurocrine Biosciences Inc — how do they compare? Flagstar Bank NA trades at $15.36 (market cap $6.26B), while Neurocrine Biosciences Inc trades at $171.47 (market cap $17.30B). The key difference: Neurocrine Biosciences Inc is far larger — about 2.8× Flagstar Bank NA's market cap, and Flagstar Bank NA pays a 0.27% dividend while Neurocrine Biosciences Inc pays none. Which is the better fit depends on your goals.
| FLG | NBIX | |
|---|---|---|
Market Cap | $6.26B | $17.30B |
Sector | Financials | Health |
52-Week High | $15.28 | $180.55 |
52-Week Low | $10.72 | $123.10 |
Dividend Yield | 0.27% | — |
Enterprise Value | — | $16.39B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FLG trades at $15.285, up 2.17% today, with a bullish technical signal from moving averages and a consensus analyst price target of $17.05. Recent earnings beat expectations in Q4 2025 and Q1 2026, though the company remains unprofitable on an annual basis with a net income margin of -2.71% in 2026. Positive developments include a proprietary technology transformation and a recent dividend declaration.
The outlook is cautiously optimistic, supported by analyst buy ratings and improving fundamentals, but risks include persistent negative profitability and high interest expenses. Upside is tied to continued execution on the turnaround and future earnings growth.
Neurocrine Biosciences (NBIX) trades at $171.81, down slightly by 0.1% on the day, with a bullish technical outlook supported by moving averages. The stock shows strong fundamentals with consistent earnings beats, including Q1 2026 EPS of $1.94 versus $1.22 expected, and robust profitability metrics like a 98.17% gross margin. Recent news highlights pipeline advancements and a Zacks upgrade to Strong Buy, reflecting positive sentiment.
Outlook remains positive with a consensus price target of $195.75, implying 14% upside. Key opportunities include sustained revenue growth and pipeline progress, while risks involve execution on recent acquisitions and competitive pressures. The stock is well-positioned for momentum but requires monitoring of Q2 2026 results due July 30.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Flagstar Bank NA
Flagstar Bank is a prominent US financial institution and a subsidiary of New York Community Bancorp. It provides commercial banking, mortgage services, and diverse personal finance products.
Read more on FLG →About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →
